Premium
Plasma sex hormone binding globulin in patients with prostatic carcinoma
Author(s) -
Grasso Marco,
Buonaguidi Arturo,
Mondina Roberto,
Borsellino Giovanni,
Lania Caterina,
Banfi Giuseppe,
Rigatti Patrizio
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900715)66:2<354::aid-cncr2820660225>3.0.co;2-n
Subject(s) - sex hormone binding globulin , medicine , hyperplasia , prostate , globulin , endocrinology , carcinoma , hormone , cancer , androgen
The concentrations of sex hormone binding globulin (SHBG) were measured in the plasma of 56 men, who were 47 to 85 years of age, by time‐resolved immunofluorometric assay with a monoclonal antibody. Twenty‐five of the men had untreated carcinoma of the prostate and 17 had untreated prostatic hyperplasia. There were 14 healthy control subjects. SHBG levels were significantly higher in patients with prostatic carcinoma (37.6 ± 8.4 nmol/1) than in those with prostatic hyperplasia (24.5 ± 5.2 nmol/1; P < 0.05) or control subjects (14.9 ± 2.8 nmol/1; P < 0.01). It is not known why SHBG levels are higher in patients with carcinoma or hyperplasia of the prostate. The contradictory results obtained in other studies may be due to heterogeneity of the binding globulin causing its values to vary in the different assays used.